Jazz Pharmaceuticals : Corporate Overview

May 2024

Corporate Overview

Innovating to Transform the Lives of Patients and Their Families

Caroline

Rylaze® patient diagnosed withMayALL2024 / LBL

Transforming Lives. Redefining Possibilities.

Caution Concerning Forward-Looking Statements

This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the Company's 2024 financial guidance and the Company's expectations related thereto and anticipated catalysts; the Company's expectations for total revenue growth, sleep revenue growth, neuroscience revenue growth and oncology revenue growth and anticipated product sales; expectations of growth in net sales of Xywav, Epidiolex/Epidyolex and Rylaze combined; the Company's expectations of additional Epidyolex ex-U.S. launches and indication expansion through 2024; expectations with respect to royalties from Xyrem authorized generic products (AG products); the Company's expectations of growth of Xywav in IH and that Xywav will remain the oxybate of choice; Vision 2025 and the Company's progress related thereto; the Company's development, regulatory and commercialization strategy; the Company's expectation of delivering at least five additional novel product approvals by the end of the decade and expectations with respect to potential corporate development; the advancement of pipeline programs and the timing of development activities, regulatory activities and submissions related thereto; the Company's expectations with respect to its products and product candidates and the potential of the Company's products

and product candidates, including the potential of Zanidatamab to be more than a two billion dollar market opportunity, and the potential regulatory path related thereto; the Company's capital allocation and corporate development strategy; the potential successful future development, manufacturing, regulatory and commercialization activities; the Company's expectation of sustainable growth and meaningful value and the ability of near-term catalysts to drive substantial value creation; growing and diversifying the Company's revenue, investing in its pipeline of novel therapies, and delivering innovative therapies for patients and potential benefits of such therapies; the Company's ability to realize the commercial potential of its products and growth opportunities; planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof, including late-stage readouts through 2024/early 2025; the Company's clinical trials confirming clinical benefit or enabling regulatory submissions; planned or anticipated regulatory submissions and filings, and the anticipated timing thereof; potential regulatory approvals; and other statements that are not historical facts. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of and revenue from Xywav, Rylaze, Epidiolex/Epidyolex and other products; the introduction of new products into the U.S. market that compete with, or otherwise disrupt the market for, the Company's oxybate products and other products and product candidates; effectively launching and commercializing the Company's other products and product candidates; the successful completion of development and regulatory activities with respect to the Company's product candidates; obtaining and maintaining adequate coverage and reimbursement for the Company's products; the time-consuming and uncertain regulatory approval process, including the risk that the Company's current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all, including the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the Company's business operations and financial results; geopolitical events, including the conflict between Russia and Ukraine and related sanctions; macroeconomic conditions, including global financial markets, rising interest rates and inflation and recent and potential banking disruptions; regulatory initiatives and changes in tax laws; market volatility; protecting and enhancing the Company's intellectual property rights and the Company's commercial success being dependent upon the Company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; delays or problems in the supply or manufacture of the Company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired product candidates, products and businesses; the

Company's ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the Company's cash flows and capital resources; the Company's ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the Company's ability to meet its projected long-term goals and objectives, including as part of Vision 2025, in the time periods that the Company anticipates, or at all, and the inherent uncertainty and significant judgments and assumptions underlying the Company's long-term goals and objectives; fluctuations in the market price and trading volume of the Company's ordinary shares; restrictions on repurchases of capital stock; the timing and availability of alternative investment opportunities; and other risks and uncertainties affecting the Company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2023 as supplemented by the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and future filings and reports by the Company. Other risks and uncertainties of which the Company is not currently aware may also affect the Company's forward- looking statements and may cause actual results and the timing of events to differ materially from those anticipated.

This presentation contains long-term and other financial targets of the Company relating to Vision 2025, including with respect to long-term total revenue and adjusted operating margin improvement targets, each of which are forward-looking statements. While these financial targets were prepared in good faith, no assurance can be made regarding future results or events. These financial targets are based on historical performance trends and management outlook that is dependent in principal part on successfully achieving targets for 2024; management's assumptions and estimates regarding Xywav adoption in IH, the effects of competition from AG Products and potential launch of generic versions of sodium oxybate and the level of AG Product royalties to the Company, the safety and efficacy profiles of competitive product launch(es) in narcolepsy and IH, and estimates of the size of the eligible IH patient population for Xywav; estimates of the size of the eligible patient populations that may ultimately be served by Epidiolex/Epidyolex, new patient market share, duration of therapy, and the safety and efficacy profiles of therapies competing with Epidiolex/Epidyolex; patient market share, duration of therapy, and the safety and efficacy profiles of therapies competing with the Company's oncology products; and the successful outcomes of ongoing and planned clinical trials. In addition, the Company's long-term revenue target assumes revenue contribution from growth opportunities related to pipeline development and potential corporate development opportunities that may not be realized in a timely manner, or at all. The estimates and assumptions underlying these financial targets involve significant judgments with respect to, among other things, future economic, competitive, regulatory, market and financial conditions, as well as future clinical and regulatory outcomes and future business decisions and corporate development opportunities that may not be realized, and that are inherently subject to significant business, economic, competitive and regulatory risks and uncertainties, including, among other things, the risks and uncertainties described above and business and economic conditions affecting the biotechnology industry generally, all of which are difficult to predict and many of which are outside the control of the Company. There can be no assurance that the underlying assumptions and estimates will prove to be accurate or that these financial targets will be realized and the Company's actual results may differ materially from those reflected in these financial targets. In addition, these financial targets are Company goals that should not be construed or relied upon as financial guidance and should not otherwise be relied upon as being necessarily indicative of future results, and investors are otherwise cautioned not to place undue reliance on these financial targets. In preparing this presentation, the Company has relied upon and assumed, without independent verification, the accuracy and completeness of industry and market information from public sources or provided to the Company by third parties, which information involves assumptions and limitations, and you are cautioned not to give undue weight to such information.

2 May 2024

Transforming Lives. Redefining Possibilities.

Non-GAAP Financial Measures

To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presentation. The Company presents non-GAAP adjusted net income (and the related per share measure) and certain line item components. Non-GAAP adjusted net income (and the related per share measure) and its line item components exclude from GAAP reported net income (loss) (and the related per share measure) and its line item components certain items, as detailed in the reconciliation tables that follow in the Appendix hereto, and in the case of non-GAAP adjusted net income (and the related per share measure), adjust for the income tax effect of the non-GAAP adjustments. In this regard, the components of non-GAAP adjusted net income, including non-GAAP adjusted cost of product sales, SG&A (selling, general and administrative) expenses and R&D (research and development) expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP adjusted net income measure. The Company also presents non-GAAP adjusted operating margin and projected non-GAAP adjusted operating margin improvement. Non-GAAP adjusted operating margin is calculated as total revenues less non-GAAP adjusted cost of product sales, SG&A expenses and R&D expenses divided by total revenues. Non-GAAP adjusted cost of product sales, SG&A expenses and R&D expenses exclude certain line item components from GAAP reported cost of product sales, SG&A expenses and R&D expenses, as detailed in the non-GAAP adjusted operating margin reconciliation tables that follow in the Appendix hereto. The Company also uses a non-GAAP net leverage ratio calculated as net debt (defined as total GAAP debt, net of cash, cash equivalents and investments) divided by non-GAAP adjusted EBITDA for the most recent period of four consecutive completed fiscal quarters. EBITDA is defined as net income before income taxes, interest expense, depreciation and amortization. Adjusted EBITDA is defined as EBITDA further adjusted to exclude certain other charges and adjustments as detailed in the non-GAAP net leverage ratio reconciliation table that follows in the Appendix hereto and is calculated in accordance with the definition of Adjusted Consolidated EBITDA as set out in the Company's credit agreement entered into in May 2021 (the Credit Agreement). Investors should note that a reconciliation of projected 2025 non-GAAP adjusted cost of product sales, SG&A and R&D expenses, which are used to calculate projected non-GAAP adjusted operating margin and the related projected percentage improvement from 2021 to 2025, to projected 2025 GAAP cost of product sales, SG&A and R&D expenses is not provided because the Company cannot do so without unreasonable efforts due to the unavailability of information needed to calculate reconciling items and due to the variability, complexity and limited visibility of comparable GAAP measures and the reconciling items that would be excluded from the non-GAAP financial measures in future periods. For example, the non-GAAP adjustment for share-based compensation expense requires additional inputs such as the number and value of awards granted that are not currently ascertainable. Investors should note that the amounts of reconciling items between actual non-GAAP adjusted cost of product sales, SG&A and R&D expenses and actual GAAP cost of product sales, SG&A and R&D expenses could be significant such that actual GAAP cost of product sales, SG&A and R&D expenses for 2025 would vary significantly from the projected adjusted cost of product sales, SG&A and R&D expenses for 2025 used to calculate projected non-GAAP adjusted operating margin and the related projected percentage improvement from 2021 to 2025.

The Company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts and that each of these non-GAAP financial measures, when considered together with the Company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the Company's results from period to period and to its forward-looking guidance, and to identify operating trends in the Company's business and to understand the Company's ability to delever. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the Company's financial performance. The Company's management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the Company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for the Company's management, the Company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the Company uses in assessing its own operating performance and making operating decisions. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles in the reconciliation tables that follow. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by the Company in this presentation and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

3 May 2024

A Leading Growth-Oriented Biopharma Company

~2.8K

Employees

Worldwide

8

Medicines

Commercialized1

>750

R&D

Employees

40

R&D

Programs2

R&D = research and development. 1https://www.jazzpharma.com/medicines/our-medicines/2https://www.jazzpharma.com/science/pipeline/

4

May 2024

William

Xywav patient living with IH

IH = idiopathic hypersomnia.

Our Purpose

is to innovate to transform the lives of patients

and their families.

Who We Are

We are focused on developing life-changing medicines for people with serious diseases, often with limited or no therapeutic options, so they can live their lives more fully.

Kasen and his mom Brittany

Epidiolex patient living with Dravet syndrome

5 May 2024

Jazz in 2024: Multiple near-term growth drivers, significant pipeline

catalysts and well-positioned to deliver meaningful value

COMMERCIAL	PIPELINE	CORPORATE
DEVELOPMENT
	Multiple near-term catalysts
Expect double-digit	Well-positioned to be
targeting significant market
percentage revenue growth	opportunities	partner of choice, with
across combined key growth	Submitted zanidatamab	financial strength to
drivers YoY1	transact
	BLA seeking accelerated
	approval in 2L BTC

Note: near-term growth drivers and pipeline catalysts are anticipated based on expectations for 2024; for further information, please see "Caution Concerning Forward-Looking Statements".	6	May 2024
2L = second-line, BLA = biologics license application; BTC = biliary tract cancer, YoY = Year-over-year, FY24 vs. FY23. 1Key growth drivers consist of Xywav, Epidiolex, Rylaze.

Strong Track Record of Corporate Development Success

WELL-POSITIONED TO BE A PARTNER OF CHOICE

Orphan Medical

Acquisition

Established Jazz's sleep franchise

2005

2012

EUSA	Celator
Acquisition	Acquisition
Expanded oncology footprint,	Strengthened
set the stage for Rylaze	hem/onc franchise
2012	2016
2014

GW Pharma

Acquisition

Transformative transaction that rapidly diversified revenues

2021

20192022

Azur Pharma	Gentium
Merger	Acquisition
Established Jazz as	Expanded commercial
global biopharmaceutical	portfolio in rare / orphan
company	diseases

Zepzelca	Zanidatamab
Licensing Agreement	Licensing Agreement
Set stage for future oncology	$2B+ peak potential,
growth in solid tumors, including	multiple indications1
zanidatamab

2024 - 2025: TARGETING CORPORATE DEVELOPMENT OPPORTUNITIES

TO DRIVE TOP-LINE REVENUE GROWTH AND DIVERSIFICATION

Note: Timeline shows select corporate development activity since 2005. Hem/onc = hematology & oncology. 1Pending regulatory approval.

7

May 2024

Vision 2025

Vision 2025 is Built on Our Core Strengths

COMMERCIAL	PIPELINE	OPERATIONAL
		EXCELLENCE

Executing successful launches	Ability to invest meaningfully in R&D	Disciplined capital allocation
#1 treatment in narcolepsy	Expanded R&D capabilities
#1 branded epilepsy treatment	Breadth and depth of pipeline	Flexibility to invest in growth drivers
Rapidly growing oncology business	Strategic R&D collaborations

$5B	≥5	5%2
in revenue in 2025, including $0.5B	Novel product approvals1	Adjusted operating margin3
from corporate development		improvement 20214 to 2025

Vision 2025 represents Jazz estimates of future performance. R&D = research and development. 1Targeted by the end of the decade; 2Five percentage points; 3Adjusted operating margin is a non-GAAP financial measure, for	9	May 2024
further information, see "Non-GAAP Financial Measures"; 42021, 2022, 2023, and projected 2024 adjusted operating margin calculation is included in the Appendix for reference.

On Track to Deliver on 2024 Guidance and Objectives

COMMERCIAL

PIPELINE

OPERATIONAL EXCELLENCE

Growing and diversified revenues

Sleep1

• Xywav® revenues grew 14% YoY
• Expect Xywav to remain oxybate of choice

Epidiolex®

• Epidiolex revenues grew 5% YoY
• Expect further data generation to support additional growth

Oncology

• Oncology revenues grew 13% YoY
• Rylaze® revenues grew 20% YoY
• Zepzelca® revenues grew 12% YoY

Multiple near-term,late-stage catalysts targeting significant market opportunities

Zanidatamab:

• Completed BLA in 2L BTC; expect to launch in 2025 or earlier
• 1L BTC confirmatory trial ongoing
• Plan to initiate Phase 3 EMPOWHER breast cancer study in 2H24
• Targeting late-2024for Phase 3 top-line PFS data in GEA

Suvecaltamide: Top-line data from Phase 2b trial in ET expected late 1H24

Epidyolex: Phase 3 top-line data readout in Japan expected in 2H24

Zepzelca: Phase 3 top-line data readout in ES 1L SCLC in combination with Tecentriq®

expected end of 2024 / early 2025

Disciplined capital allocation enables

investment in growth

Affirmed 2024 Guidance:

•	Total revenues	$4.0B - $4.2B
•	ANI2	$1.275B - $1.350B
•	Adjusted EPS2	$18.15 - $19.35

Continued top-line growth in 2024:

• Total revenues +7% at guidance midpoint
• Expect double-digit percentage growth of Xywav, Epidiolex, and Rylaze combined

Leverage cash flow to support growth

• Cash3 at end of 1Q24: $1.8B
• Strong 1Q24 operating cash flow of $267M

R&D investment to support multiple near-term catalysts

1L = first line; 2L = second line; ANI = Adjusted net income; BLA = biologics license application; BTC = Biliary tract cancer; EPS = earnings per share; ES = extensive stage; ET = essential tremor; GEA = gastroesophageal adenocarcinoma; PFS =
progression-free survival; R&D = Research & Development; SCLC = small stage lung cancer; YoY = Year-over-year, 1Q24 vs. 1Q23. 1Sleep therapeutic area consists of Xywav, Xyrem and high-sodium oxybate AG royalties; 2Non-GAAP adjusted net income	10	May 2024
(and the related per share measure) are non-GAAP financial measures; for further information, see "Non-GAAP Financial Measures" and reconciliation tables in the Appendix; 3Cash, cash equivalents and investments.